- Featured Product
- KD/KO Validated
PARP1 Polyklonaler Antikörper
PARP1 Polyklonal Antikörper für WB, IHC, IF/ICC, IF-P, FC (Intra), IP, ELISA
Wirt / Isotyp
Kaninchen / IgG
Getestete Reaktivität
human, Maus, Ratte und mehr (5)
Anwendung
WB, IHC, IF/ICC, IF-P, FC (Intra), IP, CoIP, ChIP, ELISA
Konjugation
Unkonjugiert
Kat-Nr. : 13371-1-AP
Synonyme
Galerie der Validierungsdaten
Geprüfte Anwendungen
Erfolgreiche Detektion in WB | HeLa-Zellen, C6-Zellen, Jurkat-Zellen, mit Cobaltchlorid behandelte HeLa-Zellen, mit Fas-Antikörper behandelte HeLa-Zellen, THP-1-Zellen |
Erfolgreiche IP | K-562-Zellen |
Erfolgreiche Detektion in IHC | Maus-Kolongewebe, humanes Leberkarzinomgewebe, humanes Lungenkarzinomgewebe, humanes Mammakarzinomgewebe, Maushodengewebe Hinweis: Antigendemaskierung mit TE-Puffer pH 9,0 empfohlen. (*) Wahlweise kann die Antigendemaskierung auch mit Citratpuffer pH 6,0 erfolgen. |
Erfolgreiche Detektion in IF-P | Maushodengewebe |
Erfolgreiche Detektion in IF/ICC | HEK-293-Zellen, MCF-7-Zellen |
Erfolgreiche Detektion in FC (Intra) | K-562-Zellen |
Empfohlene Verdünnung
Anwendung | Verdünnung |
---|---|
Western Blot (WB) | WB : 1:1000-1:8000 |
Immunpräzipitation (IP) | IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate |
Immunhistochemie (IHC) | IHC : 1:1000-1:4000 |
Immunfluoreszenz (IF)-P | IF-P : 1:50-1:500 |
Immunfluoreszenz (IF)/ICC | IF/ICC : 1:50-1:500 |
Durchflusszytometrie (FC) (INTRA) | FC (INTRA) : 0.40 ug per 10^6 cells in a 100 µl suspension |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, check data in validation data gallery |
Veröffentlichte Anwendungen
KD/KO | See 5 publications below |
WB | See 574 publications below |
IHC | See 23 publications below |
IF | See 15 publications below |
IP | See 8 publications below |
CoIP | See 2 publications below |
ChIP | See 2 publications below |
Produktinformation
13371-1-AP bindet in WB, IHC, IF/ICC, IF-P, FC (Intra), IP, CoIP, ChIP, ELISA PARP1 und zeigt Reaktivität mit human, Maus, Ratten
Getestete Reaktivität | human, Maus, Ratte |
In Publikationen genannte Reaktivität | human, Affe, Hausschwein, Hund, Maus, Ratte, Rind, Pilz |
Wirt / Isotyp | Kaninchen / IgG |
Klonalität | Polyklonal |
Typ | Antikörper |
Immunogen | PARP1 fusion protein Ag4193 |
Vollständiger Name | poly (ADP-ribose) polymerase 1 |
Berechnetes Molekulargewicht | 1014 aa, 113 kDa |
Beobachtetes Molekulargewicht | 113-116 kDa, 89 kDa |
GenBank-Zugangsnummer | BC037545 |
Gene symbol | PARP1 |
Gene ID (NCBI) | 142 |
Konjugation | Unkonjugiert |
Form | Liquid |
Reinigungsmethode | Antigen-Affinitätsreinigung |
Lagerungspuffer | PBS mit 0.02% Natriumazid und 50% Glycerin pH 7.3. |
Lagerungsbedingungen | Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA. |
Hintergrundinformationen
PARP1 (poly(ADP-ribose) polymerase 1) is a nuclear enzyme catalyzing the poly(ADP-ribosyl)ation of many key proteins in vivo. The normal function of PARP1 is the routine repair of DNA damage. Activated by DNA strand breaks, the PARP1 is cleaved into an 85 to 89-kDa COOH-terminal fragment and a 24-kDa NH2-terminal peptide by caspases during the apoptotic process. The appearance of PARP fragments is commonly considered as an important biomarker of apoptosis. In addition to caspases, other proteases like calpains, cathepsins, granzymes and matrix metalloproteinases (MMPs) have also been reported to cleave PARP1 and gave rise to fragments ranging from 42-89-kDa. This antibody was generated against the C-terminal region of human PARP1 and it recognizes the full-length as well as the cleavage of the PARP1.
Protokolle
Produktspezifische Protokolle | |
---|---|
WB protocol for PARP1 antibody 13371-1-AP | Protokoll herunterladen |
IHC protocol for PARP1 antibody 13371-1-AP | Protokoll herunterladen |
IF protocol for PARP1 antibody 13371-1-AP | Protokoll herunterladen |
IP protocol for PARP1 antibody 13371-1-AP | Protokoll herunterladen |
Standard-Protokolle | |
---|---|
Klicken Sie hier, um unsere Standardprotokolle anzuzeigen |
Publikationen
Species | Application | Title |
---|---|---|
Cell Res Mannose antagonizes GSDME-mediated pyroptosis through AMPK activated by metabolite GlcNAc-6P | ||
Mol Cancer YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer. | ||
Exp Mol Med Protective effect of hepatocyte-enriched lncRNA-Mir122hg by promoting hepatocyte proliferation in acute liver injury | ||
Nat Commun The ATM and ATR kinases regulate centrosome clustering and tumor recurrence by targeting KIFC1 phosphorylation. | ||
Rezensionen
The reviews below have been submitted by verified Proteintech customers who received an incentive for providing their feedback.
FH K. (Verified Customer) (10-26-2023) | this antibody worked well, but some times we need to add it at high concentrations
|
FH Priscila (Verified Customer) (04-25-2023) | Very clean detection on western blotting. Sharp bands, and the p89 proteolytic fragment of PARP1 is detectable (tested conditions: 25µg of protein lysate and 1:2,500 dilution for endogenous PARP1 in HEK293T cells).
|
FH Ruchi (Verified Customer) (12-09-2022) | The Ab was used for IF at a dilution of 1:100 for staining mice skin wounds. This is a nuclear protein and so required an additional time for fixation (30 minutes in 4% paraformaldehyde) and permeabilization by chilled methanol for 10 minutes. The blocking buffer used was 4% BSA.
|
FH Marina (Verified Customer) (05-30-2022) | In the blot we could detect native PARP1 as well as its cleaved 89 kDa form after PARP inhibitor treatment
|
FH Huanzhou (Verified Customer) (04-08-2022) | This product works well for WB.
|
FH Azita (Verified Customer) (06-02-2021) | Western blot analysis using PARP1 polyclonal antibody in NSC34 cell line at dilution of 1:500.
|
FH Brandon (Verified Customer) (02-01-2019) | Detected Full-length and cleaved PARP-1. Also detected a smaller fragment in mouse mouse liver tissue.
|